KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
239 (255 working days)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
KEYTRUDA® (pembrolizumab), in combination with enfortumab vedotin, is indicated for the first-line reatment of adult patients with locally advanced or etastatic urothelial carcinoma (mUC).